AU2023229221A1 - Use of iptacopan for the treatment of lupus nephritis - Google Patents

Use of iptacopan for the treatment of lupus nephritis Download PDF

Info

Publication number
AU2023229221A1
AU2023229221A1 AU2023229221A AU2023229221A AU2023229221A1 AU 2023229221 A1 AU2023229221 A1 AU 2023229221A1 AU 2023229221 A AU2023229221 A AU 2023229221A AU 2023229221 A AU2023229221 A AU 2023229221A AU 2023229221 A1 AU2023229221 A1 AU 2023229221A1
Authority
AU
Australia
Prior art keywords
iptacopan
subject
dose
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023229221A
Other languages
English (en)
Inventor
Janina LINNIK
Matthias Meier
Nicholas Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2023229221A1 publication Critical patent/AU2023229221A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023229221A 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis Pending AU2023229221A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316623P 2022-03-04 2022-03-04
US63/316,623 2022-03-04
PCT/IB2023/052010 WO2023166487A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
AU2023229221A1 true AU2023229221A1 (en) 2024-08-15

Family

ID=85704041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023229221A Pending AU2023229221A1 (en) 2022-03-04 2023-03-03 Use of iptacopan for the treatment of lupus nephritis

Country Status (10)

Country Link
US (1) US20250195492A1 (https=)
EP (1) EP4486343A1 (https=)
JP (1) JP2025507830A (https=)
KR (1) KR20240155291A (https=)
CN (1) CN118785906A (https=)
AU (1) AU2023229221A1 (https=)
CA (1) CA3248808A1 (https=)
IL (1) IL314494A (https=)
MX (1) MX2024010644A (https=)
WO (1) WO2023166487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119656165A (zh) * 2023-09-20 2025-03-21 上海美悦生物科技发展有限公司 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN120208923A (zh) 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Also Published As

Publication number Publication date
EP4486343A1 (en) 2025-01-08
IL314494A (en) 2024-09-01
JP2025507830A (ja) 2025-03-21
WO2023166487A1 (en) 2023-09-07
CA3248808A1 (en) 2023-09-07
US20250195492A1 (en) 2025-06-19
KR20240155291A (ko) 2024-10-28
MX2024010644A (es) 2024-09-06
CN118785906A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
US20240025975A1 (en) Administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20190099429A1 (en) Cenicriviroc for the treatment of fibrosis
US20200360347A1 (en) Cenicriviroc for the treatment of fibrosis
AU2023229221A1 (en) Use of iptacopan for the treatment of lupus nephritis
EP3185881B1 (en) Methods, agents and compositions for treatment of inflammatory conditions
CN114144185A (zh) 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
JP2025148495A (ja) Ｂ因子阻害剤の使用方法
EP4355329A1 (en) Method of treating an autoimmune hematological disorder
KR20240004947A (ko) 비정형 용혈성 요독 증후군 치료용 입타코판
Baldini et al. From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials
US20170014386A1 (en) Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
KR20250150635A (ko) 인자 b 억제제의 사용 방법
Appel et al. New diagnostic tests and new therapies for glomerular diseases
Barratt et al. Atacicept in IgA Nephropathy (IgAN): Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs. Placebo with a Focus on COVID-19: SA-PO884
WO2025172910A1 (en) Factor b inhibitors for treatment of anca-associated vasculitis
Terkawi et al. Lipoprotein apheresis for anti-nephrin antibody–positive steroid-resistant nephrotic syndrome: a pediatric case report
Ingold et al. Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report
Soler et al. Treatment of Idiopathic Membranous Nephropathy (IMN)
Veldandi et al. An adaptive, dose-exploration, Phase 2 trial evaluating efficacy and safety of iptacopan in combination with standard-of-care with and without oral corticosteroids in active lupus nephritis